Hyperinsulinemia: an early biomarker of metabolic dysfunction
Frontiers in Clinical Diabetes and Healthcare · 02.05.2023 · 4
DOI: 10.3389/fcdhc.2023.1159664 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Clinical Diabetes and Healthcare, online erschienen am 02.05.2023. Verfasst von Rama A Vaidya und 10 weiteren Autor:innen. Beteiligte Einrichtung: Kasturba Health Society- Medical Research Center, Mumbai, India. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hyperinsulinemia in the absence of impaired glucose tolerance and normal HbA1c is considered indicative of pre-diabetes. Very few Indian studies have focused on hyperinsulinemia particularly in young adults. The present study aimed to determine whether hyperinsulinemia may be present despite HbA1c being normal.
Methods
This was a cross–sectional study conducted on adolescents and young adults aged 16-25 years living in Mumbai, India. The participants attended various academic institutions and were those who underwent screening as the first step of a clinical trial for studying the efficacy of almond intake in prediabetes.
Results
Among this young population (n=1313), 4.2% (n=55) of the participants were found to be prediabetic (ADA criteria) and 19.7% of them had HbA1c levels between 5.7%-6.4%. However, almost, 30.5% had hyperinsulinemia inspite of normal blood glucose levels and normal HbA1c. Among those with HbA1c<5.7 (n=533), 10.5% (n=56) participants had fasting insulin>15 mIU/L and a higher percentage (39.4%, n=260) had stimulated insulin above 80 mIU/L. These participants had higher mean anthropometric markers than those with normal fasting and/or stimulated insulin.
Conclusion
Hyperinsulinaemia in the absence of impaired glucose tolerance and normal HbA1c may provide a much earlier indicator of detection for risk of metabolic disease and progression to metabolic syndrome and diabetes mellitus.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kasturba Health Society- Medical Research Center, Mumbai, India.
- Sir Vithaldas Thackersey College of Home Science (Autonomous), Shreemathi Nathibai Damodar Thackersey Women's University, Mumbai, India.
- Nurture Health Solutions, Mumbai, India.
- Clinical and Endocrine Laboratory, Kasturba Health Society Medical Research Centre, Mumbai, India.
- FamPhy: Gurgaon, Haryana, India.
Zitieren
APA
Vaidya, R. A., Desai, S., Moitra, P., Salis, S., Agashe, S., Battalwar, R., Mehta, A., Madan, J., Kalita, S., Udipi, S. A., & Vaidya, A. B. (2023). Hyperinsulinemia: an early biomarker of metabolic dysfunction. Frontiers in Clinical Diabetes and Healthcare, 4. https://doi.org/10.3389/fcdhc.2023.1159664
Vancouver
Vaidya RA, Desai S, Moitra P, Salis S, Agashe S, Battalwar R, et al. Hyperinsulinemia: an early biomarker of metabolic dysfunction. Frontiers in Clinical Diabetes and Healthcare. 2023;4. doi:10.3389/fcdhc.2023.1159664
BibTeX
@article{Vaidya2023,
author = {Vaidya, Rama A and Desai, Sharvari and Moitra, Panchali and Salis, Sheryl and Agashe, Shubhada and Battalwar, Rekha and Mehta, Anushree and Madan, Jagmeet and Kalita, Soumik and Udipi, Shobha A and Vaidya, Ashok B},
title = {Hyperinsulinemia: an early biomarker of metabolic dysfunction},
journal = {Frontiers in Clinical Diabetes and Healthcare},
year = {2023},
volume = {4},
doi = {10.3389/fcdhc.2023.1159664}
}
EUVIMED